Strata Oncology Enrolls First Patient in Strata PATH Trial

Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced enrollment of the first patient in the Strata Precision Indications for Approved THerapies (Strata PATH^TM) trial, a prospective pan-tumor therapeutic trial designed to evaluate the efficacy and safety of multiple FDA-approved cancer therapies in new, biomarker-guided patient populations.